LLY News and Press, Eli Lilly and Company

Lilly's EBGLYSS (lebrikizumab-lbkz) is the first and only selective IL-13 inhibitor to deliver positive Phase 3 outcomes in patients aged six months to 18 years with moderate-to-severe atopic dermatitis PR Newswire In the Phase 3 ADorable-1 study, 63% of patients achieved meaningfu...

2026-03-16 05:25:51 ET More on the markets Recession Inbound? The Warning Signs Are Everywhere 6 ETF Mistakes That Quietly Destroy Long-Term Returns The Rotation Trade Collapsed - Where To Hide Now? SA Asks: Is the U.S. economy heading towards stagflation? ...

2026-03-15 23:25:00 ET The following segment was excerpted from the PGIM Jennison Health Sciences Fund Q4 2025 Commentary. ... Read the full article on Seeking Alpha For further details see: PGIM Jennison Health Sciences Fund Q4 2025 Key ...

2026-03-14 09:48:29 ET More on GSK, Amgen Amgen: MariTide And Osteoporosis Sales Fuel The Rally GSK plc (GSK) Presents at Barclays 28th Annual Global Healthcare Conference Transcript Amgen Inc. (AMGN) Presents at Leerink Global Healthcare Conference 2026 Transcript ...

2026-03-13 18:50:00 ET Over the past two years, Eli Lilly (NYSE: LLY) has established itself as the leader in the weight loss market. That's thanks to the company's tirzepatide, a compound sold under the brand name Zepbound in anti-obesity (and Mounjaro in treating diabetes) that ...

2026-03-13 16:54:10 ET Investment Overview: Understanding Rationale For A Sell Call On Novo Stock Part 1 - Semaglutide's Meteoric Rise Was Unsustainable Read the full article on Seeking Alpha For further details see: Novo Nordisk - Enough Is Enough: 5 Reasons It's Time T...

2026-03-13 12:23:00 ET ... Read the full article on Seeking Alpha For further details see: Invesco Rising Dividends Fund Q4 2025 Portfolio Activity

2026-03-13 09:15:06 ET Jefferies analyst issues BUY recommendation for LLY on March 13, 2026 12:09PM ET. The previous analyst recommendation was Buy. LLY was trading at $977.25 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analy...

2026-03-13 08:00:00 ET I track several watchlist and review each one multiple times a week. Some contain ETFs, and others have stocks. And I make them all available for public viewing. They're not my holdings; they are the securities I'm most likely to consider owning "at a price." That...

2026-03-12 16:31:13 ET More on healthcare stocks Eli Lilly Reaching For Peak GLP-1 Euphoria: Rotten Trading Momentum Since November Eli Lilly: The Weight-Loss Craze Isn't Over CagriSema Incident: The Surprise Winner And What It Means For The Novo-Lilly Rivalry ...